Literature DB >> 30970294

MicroRNA-142-3p/MALAT1 inhibits lung cancer progression through repressing β-catenin expression.

Jingyi Liu1, Weiwei Tian2, Wenbin Zhang3, Yuan Jia4, Xiaoling Yang4, Yanli Wang4, Junping Zhang4.   

Abstract

MALAT1 is well documented to be highly expressed in non-small cell lung cancer (NSCLC) and its overexpression closely associates the malignant phenotype of NSCLC cells and poor prognosis of NSCLC patients. MALAT1 is also identified to enhance β-catenin expression and under the negative regulation of miR-142-3p. However, the role of miR-142-3p/MALAT1/β-catenin in the occurrence and development of NSCLC remains unclear. The objective of this study was to explore it. The results showed that miR-142-3p expression was reduced in NSCLC tissues, while β-catenin and MALAT1 expression levels were elevated. MTT, transwell chamber, flow cytometry assays demonstrated that up-regulation of miR-142-3p with mimic transfection significantly inhibited the proliferation, migration and promoted the apoptosis of NSCLC H1299 cells, and induced a G0/G1 phase arrest and S phase reduction. Besides, miR-142-3p negatively decreased MALAT1 expression as detected by RT-PCR and luciferase reporter assays. Moreover, up-regulation of miR-142-3p decreased β-catenin expression through down-regulating MALAT1 in H1299 cells. And in vivo experiment showed that miR-142-3p up-regulation, as well as the knockdown of either β-catenin or MALAT1 significantly reduced the tumorigenesis of NSCLC cells. Taken together, our study makes clear that miR-142-3p functions as a tumor suppressor in NSCLC progression through inhibiting MALAT1/β-catenin signaling.
Copyright © 2019 The Authors. Published by Elsevier Masson SAS.. All rights reserved.

Entities:  

Keywords:  MALAT1; Non-small cell lung cancer; miR-142-3p; β-catenin

Mesh:

Substances:

Year:  2019        PMID: 30970294     DOI: 10.1016/j.biopha.2019.108847

Source DB:  PubMed          Journal:  Biomed Pharmacother        ISSN: 0753-3322            Impact factor:   6.529


  7 in total

Review 1.  Exosomal Long Non-Coding RNAs in Lung Diseases.

Authors:  Christophe Poulet; Makon-Sébastien Njock; Catherine Moermans; Edouard Louis; Renaud Louis; Michel Malaise; Julien Guiot
Journal:  Int J Mol Sci       Date:  2020-05-19       Impact factor: 5.923

2.  Prognostic value of miR-142 in solid tumors: a meta-analysis.

Authors:  Rongqiang Liu; Shiyang Zheng; Kang Yu; Yajie Yu; Chenyu Yu; Wenqing Shi; Qianmin Ge; Zhiwei Ye; Yi Shao
Journal:  Biosci Rep       Date:  2021-02-26       Impact factor: 3.840

3.  Circ_0020123 Increases ZFX Expression to Facilitate Non-Small Cell Lung Cancer Progression by Sponging miR-142-3p.

Authors:  Jiancong Lu; Ximiao Ma; Junhong Lin; Peifeng Hou
Journal:  Cancer Manag Res       Date:  2021-02-18       Impact factor: 3.989

4.  Pyroptosis-Related LncRNA Signatures Correlate With Lung Adenocarcinoma Prognosis.

Authors:  Hua Huang; Zijian Shi; Yongwen Li; Guangsheng Zhu; Chen Chen; Zihe Zhang; Ruifeng Shi; Lianchun Su; Peijun Cao; Zhenhua Pan; Hongbing Zhang; Minghui Liu; Hongyu Liu; Jun Chen
Journal:  Front Oncol       Date:  2022-03-02       Impact factor: 6.244

Review 5.  Seminal exosomes - An important biological marker for various disorders and syndrome in human reproduction.

Authors:  A S Vickram; P S Srikumar; S Srinivasan; Palanivelu Jeyanthi; K Anbarasu; S Thanigaivel; Dey Nibedita; D Jenila Rani; Karunakaran Rohini
Journal:  Saudi J Biol Sci       Date:  2021-03-17       Impact factor: 4.219

6.  The Effect of Genomic DNA Contamination on the Detection of Circulating Long Non-Coding RNAs: The Paradigm of MALAT1.

Authors:  Athina N Markou; Stavroula Smilkou; Emilia Tsaroucha; Evi Lianidou
Journal:  Diagnostics (Basel)       Date:  2021-06-25

7.  Knockdown of circ-RAD23B inhibits non-small cell lung cancer progression via the miR-142-3p/MAP4K3 axis.

Authors:  Qingyang Zhuang; Zhangzhou Huang; Wu Zhuang; Yaping Hong; Yunjian Huang
Journal:  Thorac Cancer       Date:  2022-02-02       Impact factor: 3.500

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.